Parkinson's disease (PD) is a neurodegenerative disease characterized by bradykinesia, resting tremor, rigidity, and gait disturbance. Numerous studies have demonstrated that PD is the consequence of substantial loss of substantia nigra neurons and depletion of the transmitter dopamine (DA). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes selective degeneration of the nigrostriatal dopaminergic neurons and is widely used to create an animal model of PD. 1) MPTP is converted by monoamine oxidase B to the active metabolite MPP ϩ which is accumulated intracellularly in neurons via the dopaminergic transporter. MPP ϩ produces neurotoxic effects by inhibiting the complex I of the respiratory chain in DA neurons, which ultimately results in cell death. Because of the similarity between the MPTP mouse model and PD, it is tempting to propose that a similar scenario applies to the pathogenesis of PD.
tive infrabeams was expressed as counts per 5 min. 6) Rotarod Test. The mice were trained twice daily on 2 successive days to stay on a rotating rod (Experimental Factory of Peking University Health Science Center, Beijng, China) for 120 s (speed 12 rpm). The rotarod unit consists of a rotating spindle (diameter 7.3 cm) and individual compartments for each mouse. Subsequently, the mice were tested on the rotarod three times (speed 25 rpm). The duration from the beginning of rotation to mice leaving the rotating rod was used to indicate the endurance performance during 60 s. The mean endurance performance was the mean of three performances at the given speed. All values are expressed as meanϮS.E.M. and statistical significance was evaluated using the Mann-Whitney U-test.
7)
HPLC Analysis HPLC with an electrochemical (EC) detector (Coularray, ESA, Inc., Chelmsford, MA, U.S.A.) was used to measure striatal levels of DA, 3,4-dihydroxyphenyl acetic acid (DOPAC), and homovanillic acid (HVA). 8) After the above tests, the mice were killed by decapitation, and the striata were dissected and assayed for DA, DOPAC and HVA using an HPLC-EC procedure. Striata were sonicated in 100 ml of ice-cold solution A (0.4 M HClO 4 ) and after being stored for 1 h at 4°C homogenates were centrifuged at 15000ϫg for 15 min at 4°C. Then 40 ml of solution B (20 mM sodium citrate, 300 mM K 2 HPO 4 , and 2 mM Na 2 EDTA) was added to the supernatant. After being mixed thoroughly, the solution was also stored for 1 h at 4°C and centrifuged at 15000ϫg for 15 min at 4°C. The supernatant was filtered (pore size 0.22 mm, Millipore filter) and 20 ml of supernatant was autoinjected (ESA Model 542). The mobile phase consisted of 94% 150 mM citric acid and sodium citrate buffer (pH 4.3), 100 mM Na 2 EDTA, 120 mM sodium octyl sulfate, and 6% methanol. The flow rate was 1.0 ml/min. The levels of DA and its metabolite were calculated and expressed as ng/mg tissue weight. Each group consisted of 6 animals.
Immunohistochemical Assay For immunohistochemical study, some of the animals were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) 3 d after MPTP treatment, and the brains were perfusion-fixed with 10% buffered formalin for a minimum of 2 weeks following a normal saline flush. The brains were removed 1 h after perfusion fixation at 4°C and immersed in 10% buffered formalin. Paraffin sections from the regions of the substantia nigra (5 mm thick) were mounted and immunohistochemically stained with tyrosine hydroxylase (TH). For TH immunohistochemistry, a polyclonal anti-TH antibody (Chemicon International, Temecula, CA, U.S.A.) and a Vectastain elite ABC kit (Vector Laboratories, CA, U.S.A.) were used. The paraffin sections were washed for 5 min in 10 mM phosphate-buffered saline (PBS, pH 7.4) and treated with 3% H 2 O 2 . The paraffin sections were then washed three times, for 5 min/each time in 10 mM PBS, followed by a 30-min preincubation with 10% normal goat serum. The brain sections were then incubated with anti-TH antibody (1 : 200) including 0.3% Triton X-100 overnight at 4°C. After a 15-min rinse in fresh 10 mM PBS, the sections were incubated with a biotinylated second antibody for 2 h and then administrated with an avidin-biotin peroxidase complex for 30 min at room temperature. Signals of immunoreactions were visualized with diaminobenzidene (DAB) (Sigma Chemical). 9) Microphotographs were taken with an objective lens of 10ϫ magnification.
Western Blotting For Western blot analysis, after decapitation, brains were quickly removed and the stratum and substantia nigra were rapidly dissected out on an ice-cold glass Petri dish. Samples were immediately weighed, then frozen and stored at Ϫ80°C until assay. The stratum and substantia nigra frozen at Ϫ80°C were individually homogenized in 80 mM Tris-HCl buffer (pH 7.4) containing 0.1% sodium dodecyl sulfate (SDS), 0.4 mM dithiothreitol, 2 mM EDTA, and the protease inhibitor phenylmethlysulfonyl fluoride (0.1 mM). After incubation in buffer for 30 min at 4°C, samples were centrifuged at 15000ϫg for 10 min at 4°C. Supernatants were collected and the protein concentration was determined. The Lowry protein assay was used with bovine serum albumin (BSA) as the standard for protein measurement. Protein was denatured at 100°C for 5 min in sample buffer and electrophoresed onto a 7.5% SDS-PAGE. After transfer to a nitrocellulose membrane, the blot was washed in Tris-buffered saline containing 0.05% Tween-20, then blocked with 5% BSA and 5% skim milk for 1 h and incubated with a polyclonal anti-TH antibody (Chemicon International, Temecula, CA, U.S.A.) diluted 1 : 500 overnight at 4°C. After washing, blot was incubated with goat anti-rabbit IgG linked with peroxidase diluted 1 : 1000 for 1 h. The reaction was developed with a chemiluminescence method (ECL; Amersham).
Statistical Analysis Values were expressed as meanϮS.E.M. To analyze the differences between groups, statistical analysis was conducted using t-and two-way 798 Vol. 27, No. 6 When two drugs were given, the each administration intermission was 1 h. PhGs, phenylethanoid glycosides 10 and 50 mg/kg, respectively.
ANOVA tests, while the differences in the rotarod test were analyzed using the Mann-Whitney U-test. The level of significance was set at pϽ0.05.
RESULTS

Behavioral Experiments
The results of spontaneous motor activity and rotarod tests for MPTP lesions and PhGs treatment are shown in Figs. 1 and 2 , respectively. These results strongly suggest that PhGs pretreatment reversed, at least in part, the spontaneous activity and coordinated movement impairments. The MPTP-treated group had less spontaneous motor activity and a shorter latent period in the rotarod test (pϽ0.01) compared with the control group. A significant increase in these tests is also shown in Figs. 1 and 2 due to PhGs (10, 50 mg/kg) treatment compared with the MPTP model group (pϽ0.01). Amantadine was used as a positive control and is a releaser or reuptake inhibitor of DA. Amantadine (40 mg/kg) significantly increased the spontaneous movement number and latent period on the rotating rod compared with the MPTP model group (pϽ0.01). Furthermore, the protective effects of PhGs (50 mg/kg) on MPTP-lesioned C57 mice were similar to those of amantadine (40 mg/kg) although the protective effect of PhGs was stronger than those of amantadine in the spontaneous motor test and that of PhGs was weaker than that of amantadine in the rotarod test (Figs. 1, 2) .
Level of DA The present results confirm that administration of MPTP can induce a marked decrease in DA (0.35Ϯ0.13 ng/mg tissue), DOPAC (2.08Ϯ0.75 ng/mg tissue) and HVA (1.03Ϯ0.29 ng/mg tissue) in striata but not be induced in the control group (2.65Ϯ0.73 ng/mg tissue, 6.23Ϯ0.67 ng/mg tissue and 1.83Ϯ0.09 ng/mg tissue, respectively, pϽ0.01, Table 2 ). Pretreatment with PhGs (10, 50 mg/kg) markedly enhanced the level of DA and DOPAC (pϽ0.05 or pϽ0.01) in a dose-dependent fashion. Amantadine also markedly enhanced the level of dopamine (pϽ0.01) and DOPAC (pϽ0.01) in MPTP-lesioned C57 mice. Moreover, the effect was stronger than that of PhGs (10, 50 mg/kg). These results suggest that the effects of PhGs in behavioral experiments correlated with the increase in DA levels in the striata of MPTP-lesioned C57 mice. Furthermore, PhGs caused a significant increase in both DOPAC and the DOPAC/dopamine ratio (data no shown).
Immunohistochemical Assay Typical microphotographs of TH immunostaining in the substantia nigra are shown in Fig. 3 . TH is a rate-limiting enzyme in DA synthesis. Dopaminergic neurons could easily be detected in the substantia nigra using TH antibody.
The cytoplasm and fiber of dopaminergic neurons were intensely stained with evident immunoreactive positive signals. Many dopaminergic neurons were lost in the substantia nigra following the administration of MPTP. No such pathologic changes were seen in the substantia nigra following the administration of PhGs plus MPTP. These in vivo results support and reconfirm prior results (Yanyun Li et al., unpublished observations) showing that PhGs can protect dopaminergic neurons from injuries caused by toxic MPTP in the body and nerve terminal regions.
Western Blotting TH immunoreactivity in the striatum and substantia nigra was examined by Western blotting. Figure 4 shows a band of apparent molecular weight of 60 kDa, which corresponds to the molecular weight of TH. The model group showed the lower staining intensity compared with the control group, and the intensity of the band was similar in the control group, amantadineϩMPTP group, and PhGs (50 mg/kg)ϩMPTP group, in agreement with the above immunohistochemical results. 
DISCUSSION
The present study demonstrates that PhGs can protect or rescue nigrostriatal neurons from MPTP-induced dopaminergic toxicity to the substantia nigra compacta neurons. The current in vivo data ( Table 2 (Figs. 1, 2 ) further support our current working hypothesis that PhGs can improve behavioral deficits in mice induced by MPTP, which causes a decrease in spontaneous motor activity and shortens the duration from the beginning of the rotation to mice leaving the rotating rod. The effects of PhGs are dose dependent (Figs. 1, 2) . MPTP causes an expressive lesion of the substantia nigra compacta and a significant reduction in DA levels in the striatum. 10) Our results suggest that PhGs can increase the levels of DA and its metabolites in the striata of MPTP-lesioned C57 mice. We conducted an additional experiment to observe the effect of PhGs in intact mice, and the DA level increased slightly but there was no significant difference compared with the control group. Amantadine, a noncompetitive Nmethyl-D-aspartate (NMDA) receptor antagonist known to increase DA release in the striatum, is frequently associated with L-DOPA in the treatment of PD. The effect of PhGs on increasing the DA level in the striatum is similar to that of amantadine, but that on the NMDA receptor remains to be determined. In addition, it is not known whether PhGs are releasers or reuptake inhibitors of DA. Moreover, the present data (Table 2) suggest that PhGs may alter striatal type B monoamine oxidase activity in our experimental paradigm since the ratio of DOPAC/dopamine was changed by PhGs.
It has been reported that cell death in the C57 mouse 5 or 10 d after MPTP treatment is dose dependent. 11, 12) Using TH immunoreactivity on alternate sections to identify surviving neurons in the substantia nigra compacta, we found that MPTP caused cell death in the C57 mouse substantia nigra compacta (Fig. 3) . The main component acteoside of PhGs significantly improved cell viability and protected cells from MPP Western blotting showed TH levels in the striatum and substantia nigra of each group. Molecular weight marker is shown on the left. 1, Control; 2, MPTP (30 mg/kg); 3, amantadineϩMPTP; 4, PhGs (10 mg/kg)ϩMPTP; 5, PhGs (50 mg/kg)ϩMPTP. A comparative reduction in TH immunoreactivity was seen in band 2. Band 3, 4, and 5 show that amantadine and PhGs can significantly prevent the reduction in TH. published data). Our results show that PhGs can increase the number of dopaminergic neurons in vivo in MPTP-lesioned C57 mice. TH immunoreactivity in the striatum and substantia nigra was also examined by Western blotting (Fig. 4) . The results showed a band of apparent molecular weight of 60 kDa, which corresponded to the molecular weight of TH. The model group showed lower staining intensity compared with the control group, but the intensity of the band in the PhGs (50 mg/kg)ϩMPTP group was similar to that in the control group, in agreement with the immunohistochemistry results (Fig. 3) . However, the mechanisms involved in the effect still need to be clarified, and it is suggested that the mechanisms may contribute to facilitating striatal DA release. PhGs may be hydrolyzed into smaller molecules to play a part in the action in vivo because they have a glycoside chemical structure. Studies on the metabolites of PhGs in vivo and their neuroprotective effects are ongoing in our laboratory.
